ID   17201
AC   CVCL_WY95
DR   Wikidata; Q93300030
RX   PubMed=31150822;
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Leu137Aspfs*9 (c.409_416del7); Zygosity=Unspecified (PubMed=31150822).
CC   Omics: Genomics; Whole genome sequencing; Low read coverage.
CC   Omics: Transcriptomics; RNAseq.
CC   Miscellaneous: Age at sampling and TP53 mutation cDNA coordinates from personal communication of Castillo-Tong, Dan Cacsire.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): PubMed=31150822
ST   Amelogenin: X
ST   CSF1PO: 9,12
ST   D12S391: 18,23
ST   D13S317: 12
ST   D16S539: 11,15
ST   D18S51: 14
ST   D19S433: 16.2
ST   D1S1656: 17
ST   D21S11: 29,30
ST   D2S1338: 23
ST   D3S1358: 16,18
ST   D5S818: 11
ST   D6S1043: 12,18
ST   D7S820: 12,13
ST   D8S1179: 14
ST   FGA: 20,22
ST   Penta D: 9,10
ST   Penta E: 12,14
ST   TH01: 9,9.3
ST   TPOX: 9,10
ST   vWA: 14,16
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_WY92 ! 15876
OI   CVCL_WY93 ! 16106
OI   CVCL_WY94 ! 17066
OI   CVCL_WY96 ! 17268
OI   CVCL_WY97 ! EB0405
SX   Female
AG   80Y
CA   Cancer cell line
DT   Created: 06-09-19; Last updated: 10-04-25; Version: 8
//
RX   PubMed=31150822; DOI=10.1016/j.canlet.2019.05.032;
RA   Kreuzinger C., von der Decken I., Wolf A., Gamperl M., Koller J.,
RA   Karacs J., Pfaffinger S., Bartl T., Reinthaller A., Grimm C.,
RA   Singer C.F., Braicu E.I., Cunnea P., Gourley C., Smeets D., Boeckx B.,
RA   Lambrechts D., Perco P., Horvat R., Berns E.M.J.J., Castillo-Tong D.C.;
RT   "Patient-derived cell line models revealed therapeutic targets and
RT   molecular mechanisms underlying disease progression of high grade
RT   serous ovarian cancer.";
RL   Cancer Lett. 459:1-12(2019).
//